Loading...

Brilliant Violet 605™ anti-mouse/human CD45R/B220 Antibody

Pricing & Availability
Clone
RA3-6B2 (See other available formats)
Regulatory Status
RUO
Other Names
B220
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
RA3-6B2_BV605_052112
C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
  • RA3-6B2_BV605_052112
    C57BL/6 mouse splenocytes were stained with CD45R/B220 (clone RA3-6B2) Brilliant Violet 605™ (filled histogram) or rat IgG2a, κ Brilliant Violet 605™ isotype control (open histogram).
See Brilliant Violet 605™ spectral data
Cat # Size Price Quantity Check Availability Save
103243 125 µL 168€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
103244 50 µg 210€
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD45R, also known as B220, is an isoform of CD45. It is a member of the protein tyrosine phosphatase (PTP) family with a molecular weight of approximately 180-240 kD. CD45R is expressed on B cells (at all developmental stages from pro-B cells through mature B cells), activated B cells, and subsets of T and NK cells. CD45R (B220) is also expressed on a subset of abnormal T cells involved in the pathogenesis of systemic autoimmunity in MRL-Faslpr and MRL-Fasgld mice. It plays a critical role in TCR and BCR signaling. The primary ligands for CD45 are galectin-1, CD2, CD3, and CD4. CD45R is commonly used as a pan-B cell marker; however, CD19 may be more appropriate for B cell specificity.

Product Details
Technical Data Sheet (pdf)

Product Details

Reactivity
Mouse,Human
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Abelson murine leukemia virus-induced pre-B tumor cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605™ under optimal conditions.
Concentration
µg sizes: 0.2 mg/mL
µL sizes: lot-specific (to obtain lot-specific concentration and expiration, please enter the lot number in our Certificate of Analysis online tool.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the µg size, the suggested use of this reagent is ≤0.5 µg per million cells in 100 µl volume. For immunofluorescent staining using the µl size, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605™ excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605™ is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Clone RA3-6B2 has been described to react with an epitope on the extracellular domain of the transmembrane CD45 glycoprotein which is dependent upon the expression of exon A and specific carbohydrate residues. Additional reported applications (for the relevant formats) include: immunoprecipitation1, in vitro and in vivo modulation of B cell responses2-4, immunohistochemistry of acetone-fixed frozen sections and formalin-fixed paraffin-embedded sections5,6, and spatial biology (IBEX)14,15.

Application References

(PubMed link indicates BioLegend citation)
  1. Coffman RL. 1982. Immunol. Rev. 69:5. (IP)
  2. George A, et al. 1994. J. Immunol. 152:1014. (Activ)
  3. Asensi V, et al. 1989. Immunology 68:204. (Activ)
  4. Domiati-Saad R, et al. 1993. J. Immunol. 151:5936. (Activ)
  5. Hata H, et al. 2004. J. Clin. Invest. 114:582. (IHC)
  6. Monteith CE, et al. 1996. Can. J. Vet. Res. 60:193. (IHC)
  7. Shih FF, et al. 2006. J. Immunol. 176:3438. (FC)
  8. Chang C L-T, et al. 2007. J. Immunol. 178:6984.
  9. Fazilleau N, et al. 2007. Nature Immunol. 8:753.
  10. Lang GL, et al. 2008. Blood 111:2158. PubMed
  11. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  12. del Rio ML, et al. 2011. Transpl. Int. 24:501. (FC) PubMed
  13. Murakami R, et al. 2013. PLoS One. 8:73270. PubMed
  14. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  15. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Poon E, et al. 2017. J Immunother Cancer. 10.1186/s40425-017-0268-8. PubMed
  2. Coley WD et al. 2018. F1000Research. 2018 Mar 14 [revised 2018 Jan 1] 0.5125. PubMed
  3. Cunha LD et al. 2018. Cell. 175(2):429-441 . PubMed
  4. Best SA, et al. 2018. Cell Metab. 27:935. PubMed
  5. Wang KC, et al. 2018. Immunohorizons. 2:407. PubMed
  6. Farsakoglu Y et al. 2019. Cell reports. 26(9):2307-2315 . PubMed
  7. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  8. Clancy–Thompson E, et al. 2019. EMBO J. 38:e101260. PubMed
  9. Finkin S et al. 2019. Immunity. 51(2):324-336 . PubMed
  10. Schuh E, et al. 2017. J Immunol. 198:3081. PubMed
  11. Zhang H, et al. 2019. Mol Cell. 76:110. PubMed
  12. Ghezraoui H, et al. 2018. Nature. 560:122. PubMed
  13. Sangesland M, et al. 2020. Immunity. 51(4):735-749. PubMed
  14. Treger RS, et al. 2020. Immunity. 50(2):334-347.e9.. PubMed
  15. Andersen L, et al. 2020. Cell Reports. 29(13):4447-4459.e6.. PubMed
  16. Jacque E, et al. 2015. J Exp Med. 212:883. PubMed
  17. Rios D, et al. 2015. Mucosal Immunol. 101038/mi. PubMed
  18. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  19. Kim EH, et al. 2020. Elife. 9:00. PubMed
  20. Soni C, et al. 2020. Immunity. 52(6):1022-1038.e7. PubMed
  21. Zhou X, et al. 2021. Cell Reports. 34(1):108601. PubMed
  22. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  23. Chatterjee D, et al. 2021. Cell Reports. 35(2):108996. PubMed
  24. Viant C, et al. 2021. STAR Protocols. 2(2):100389. PubMed
  25. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  26. Kim SP, et al. 2021. Cell Reports. 36(9):109626. PubMed
  27. McNamara HA, et al. 2020. Cell Host Microbe. 572:28. PubMed
  28. Biram A, et al. 2020. Bio Protoc. e3562:10. PubMed
  29. Stump CT, et al. 2021. Open Biol. 11:210245. PubMed
  30. Bourque J, et al. 2021. Heliyon. 7:e08311. PubMed
  31. Viant C, et al. 2020. Cell. 183:1298. PubMed
  32. Viant C, et al. 2021. J Exp Med. 218:. PubMed
  33. Xu JL, et al. 2022. Front Pharmacol. 13:911663. PubMed
  34. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
  35. Mittal A, et al. 2021. Sci Rep. 11:10731. PubMed
  36. Chen S, et al. 2022. Cancer Discov. :. PubMed
  37. Wang H, et al. 2022. Curr Protoc. 2:e446. PubMed
  38. Chen J, et al. 2022. Nat Commun. 13:6759. PubMed
  39. Hodgson R, et al. 2022. Commun Biol. 5:1216. PubMed
  40. Lopez DA, et al. 2022. Cell Rep. 41:111677. PubMed
  41. Mugarza E, et al. 2022. Sci Adv. 8:eabm8780. PubMed
  42. Schaefer-Babajew D, et al. 2023. Nature. 613:735. PubMed
  43. Hägglöf T, et al. 2023. Cell. 186:147. PubMed
  44. Yeh CH, et al. 2022. Immunity. 55:272. PubMed
  45. Dickerson KM, et al. 2022. Blood Cancer Discov. 3:240. PubMed
  46. Lin J, et al. 2022. Adv Sci (Weinh). 9:e2202633. PubMed
RRID
AB_11203907 (BioLegend Cat. No. 103243)
AB_2563312 (BioLegend Cat. No. 103244)

Antigen Details

Structure
Protein tyrosine phosphatase (PTP) family, 180-240 kD
Distribution

B cells, T cell subset, NK cell subset

Function
Phosphatase, T and B cell activation
Ligand/Receptor
Galectin-1, CD2, CD3, CD4
Cell Type
B cells, NK cells, T cells
Biology Area
Cell Biology, Immunology, Inhibitory Molecules, Neuroscience, Neuroscience Cell Markers
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Trowbridge IS, et al. 1993. Annu. Rev. Immunol. 12:85.
3. Kishihara K, et al. 1993. Cell 74:143.
4. Pulido R, et al. 1988. J. Immunol. 140:3851.

Gene ID
19264 View all products for this Gene ID 5788 View all products for this Gene ID
UniProt
View information about CD45R on UniProt.org
Go To Top Version: 2    Revision Date: 04/25/2013

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account